Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics Inc. reports developments tied to its macrophage- and monocyte-engineering therapeutics platform, including liver fibrosis, oncology, autoimmune-disease research, and CAR-M programs. Company updates have covered preclinical data, pipeline reprioritization, the discontinuation of the anti-HER2 program, collaboration-related programs with Moderna, and strategic alternatives for remaining assets.
Recent corporate-status news has also addressed workforce reductions, asset monetization efforts, Nasdaq suspension and delisting matters, OTCID trading under CARM, and SEC deregistration steps for the company’s common stock.
Carisma Therapeutics (Nasdaq: CARM) announced that the FDA granted Fast Track designation for CT-0525, a gene-modified cellular therapy for HER2-overexpressing solid tumors. This designation aims to expedite the development and review of therapies addressing serious conditions with unmet medical needs. The Phase 1 clinical trial is ongoing, focusing on safety, tolerability, and manufacturing feasibility. Initial data is expected by the end of 2024. The trial targets patients with advanced or metastatic solid tumors unresponsive to standard therapies.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the adjournment of its annual stockholder meeting on June 13, 2024, due to technical difficulties. The meeting will reconvene virtually on June 14, 2024, at 10:00 a.m. Eastern Time. Stockholders can attend online, vote electronically, and submit questions via a virtual audio web conference.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced its participation in the Jefferies Global Healthcare Conference. Steven Kelly, President and CEO, will join a fireside chat on June 6, 2024, at 3:00 pm ET. An audio webcast will be available on the Investor Events section of the company's website and archived for a time.
Carisma Therapeutics (Nasdaq: CARM) has dosed the first patient in its Phase 1 clinical trial of CT-0525, a novel CAR-Monocyte cellular therapy targeting HER2-overexpressing solid tumors. This marks the first human trial for CAR-Monocytes in a solid tumor setting. Initial data is anticipated by year-end 2024. The trial, open-label in design, aims to evaluate the safety, tolerability, and manufacturing feasibility of CT-0525. It will include patients with advanced or metastatic HER2-positive tumors that have not responded to standard therapies. The trial's design will be featured at the ASCO 2024 Annual Meeting.
Carisma Therapeutics Inc. (Nasdaq: CARM) reported financial results for Q1 2024 and highlighted recent business updates. The company announced CT-0525 as the lead product candidate for the anti-HER2 program, presented preclinical proof of concept data in liver fibrosis, and reported Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508. Carisma plans to treat the first patient in the CT-0525 Phase 1 clinical study in Q2 2024 and expects to have initial data by year-end 2024. The company also reported a cash balance of $56.5 million, expected to fund operations into Q3 2025.
Carisma Therapeutics Inc. (Nasdaq: CARM) presented groundbreaking preclinical data at ASGCT 2024, showcasing the efficacy of engineered macrophages in reducing liver fibrosis. The therapy demonstrated significant reductions in fibrosis in liver and lung models, offering promising solutions for metabolic dysfunction-associated diseases. Carisma plans to nominate a development candidate for its liver fibrosis program in early 2025.
Carisma Therapeutics Inc. (Nasdaq: CARM) is set to participate in The Citizens JMP Life Sciences Conference. The company, a clinical-stage biopharmaceutical firm specializing in innovative immunotherapies, will have its President and CEO, Steven Kelly, engage in a fireside chat on May 13th at 12:00 pm ET. The event will be webcasted and archived on the Investor Relations webpage.
Carisma Therapeutics Inc. (Nasdaq: CARM) has appointed Dr. Eugene P. Kennedy as the Chief Medical Officer. Dr. Kennedy, with over 15 years of experience in clinical and industry settings, will oversee Carisma's clinical development, regulatory, and medical affairs functions. His expertise in oncology and immuno-oncology is expected to positively impact the organization and advance their clinical program and pipeline.
Summary not available.
Summary not available.